Adjuvant endocrine therapy for premenopausal women with breast cancer: Patient adherence and physician prescribing practices in Mexico

被引:5
|
作者
Villarreal-Garza, Cynthia [1 ,2 ]
Mesa-Chavez, Fernanda [1 ,2 ]
Ferrigno, Ana S. [1 ,2 ]
Garza-Ramos, Cynthia De la [1 ,2 ]
Fonseca, Alan [2 ,3 ]
Villanueva-Tamez, Karen [1 ]
Campos-Salgado, Jose Y. [3 ]
Cruz-Ramos, Marlid [2 ,3 ]
Rodriguez-Gomez, David O. [1 ]
Ruiz-Cruz, Sandy [3 ]
Cabrera-Galeana, Paula [3 ]
机构
[1] Tecnol Monterrey, Hosp Zambrano Hell TecSalud, Breast Canc Ctr, Batallon San Patricio 112,14th Floor, San Pedro Garza Garcia 66278, Nuevo Leon, Mexico
[2] Joven & Fuerte Programa Atenc & Invest Mujeres Jo, Holbein 227,Int 210AB, Mexico City 03720, DF, Mexico
[3] Inst Nacl Cancerol, Dept Tumores Mamarios & Invest, San Fernando 22,Belisario Dominguez Secc 16, Mexico City 14080, DF, Mexico
来源
BREAST | 2021年 / 59卷
关键词
Breast cancer; Endocrine therapy; Adherence; Premenopausal; Prescribing practices; Mexico; CLINICAL-PRACTICE GUIDELINES; HORMONAL-THERAPY; EARLY DISCONTINUATION; OVARIAN SUPPRESSION; TAMOXIFEN; NONADHERENCE; COHORT; SURVIVORS; PERSPECTIVES; PERSISTENCE;
D O I
10.1016/j.breast.2021.05.013
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: In resource-constrained settings, data regarding breast cancer patients' adherence to endocrine therapy (ET) and physicians' prescribing practices is limited. This study aims to decrease this knowledge gap in a real-world clinical practice. Methods: Premenopausal women with stage 0-III hormone-sensitive breast cancer and receiving adjuvant ET during the past 1-5 years were identified in three Mexican referral centers. Participants' self reported ET compliance, clinicopathologic characteristics, ET-related knowledge and beliefs, experienced adverse effects, social support, and patient-physician relationships were evaluated. Physician ET prescribing practices were compared with the gold standard according to international and national guidelines to assess clinicians' adherence to standard-of-care prescription. Results: In total, 95/132 (72%) and 35/132 (27%) participants reported complete and acceptable adherence, respectively. Incomplete adherence was mainly attributed to forgetfulness, adverse effects, and unwillingness to take ET. Being employed/studying (p = 0.042), worrying about long-term ET use (p = 0.031), and experiencing >7 ET-related symptoms (p = 0.018) were associated with incomplete adherence. Guideline-endorsed regimens were prescribed in 84/132 (64%) patients, while the rest should have undergone ovarian function suppression (OFS) but instead received tamoxifen monotherapy. Conclusions: Premenopausal Mexican women self-report remarkably high rates of adequate ET adherence. However, a considerable proportion misses >1 doses/month, usually because of forgetfulness. Notably, only 64% receive standard-of-care ET due to suboptimal prescription of OFS. Interventions that remind patients to take their ET, refine physicians' knowledge on the importance of OFS in high-risk patients, and increase access to OFS could prove pivotal to enhance optimal ET implementation and adherence, which could translate into improved patient outcomes. (c) 2021 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
引用
收藏
页码:8 / 15
页数:8
相关论文
共 50 条
  • [31] Adherence to Adjuvant Endocrine Therapy in Breast Cancer Patients
    Rosso, Roberta
    D'Alonzo, Marta
    Bounous, Valentina Elisabetta
    Actis, Silvia
    Cipullo, Isabella
    Salerno, Elena
    Biglia, Nicoletta
    CURRENT ONCOLOGY, 2023, 30 (02) : 1461 - 1472
  • [32] Endocrine therapy for advanced breast cancer in premenopausal women
    Jonat, W
    ADVANCES IN ENDOCRINE THERAPY OF BREAST CANCER, PROCEEDINGS, 2004, : 105 - 114
  • [33] Male Breast Cancer and Adherence to Adjuvant Endocrine Therapy
    Lee, Inyoung
    Lee, Wan-Ju
    Calip, Gregory S.
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2016, 25 : 189 - 190
  • [34] Polypharmacy and Adherence to Adjuvant Endocrine Therapy for Breast Cancer
    Calip, Gregory S.
    Xing, Shan
    Jun, Da-Hae
    Lee, Wan-Ju
    Hoskins, Kent F.
    Ko, Naomi Y.
    JOURNAL OF ONCOLOGY PRACTICE, 2017, 13 (05) : E451 - E462
  • [35] PATIENT-REPORTED OUTCOMES AND FACTORS ASSOCIATED WITH EARLY DISCONTINUATION OF ADJUVANT ENDOCRINE THERAPY IN PREMENOPAUSAL WOMEN WITH BREAST CANCER
    Smith, Karen
    Blackford, Amanda
    Ensminger, Jennifer
    Bantug, Elissa
    Stearns, Vered
    BREAST, 2018, 41 : S25 - S26
  • [36] Adjuvant hormonal therapy for premenopausal women with breast cancer
    Brown, Regina J.
    Davidson, Nancy E.
    SEMINARS IN ONCOLOGY, 2006, 33 (06) : 657 - 663
  • [37] Adjuvant hormonal therapy for premenopausal women with breast cancer
    Emens, LA
    Davidson, NE
    CLINICAL CANCER RESEARCH, 2003, 9 (01) : 486S - 494S
  • [38] Adjuvant hormonal therapy in premenopausal women with breast cancer
    Smyth, Lillian
    Hudis, Clifford
    INDIAN JOURNAL OF MEDICAL AND PAEDIATRIC ONCOLOGY, 2015, 36 (04) : 195 - 200
  • [39] Adjuvant endocrine therapy in premenopausal breast cancer: a initial dedicated counseling: can it be useful for better adherence?
    Lesur, Anne
    Dalenc, Florence
    Beguignot, Marie
    BULLETIN DU CANCER, 2019, 106 (12) : S28 - S36
  • [40] Ovarian suppression in combination endocrine adjuvant therapy in premenopausal women with early breast cancer Response
    Chlebowski, Rowan T.
    Pan, Kathy
    Nananda, F.
    BREAST CANCER RESEARCH AND TREATMENT, 2017, 163 (03) : 633 - 634